Questions,answered

We discover new medicines by combining multi-omics biology, generative AI and our own laboratory. The platform identifies disease targets, designs molecules against them and tests the best designs experimentally.

Not currently. Our programmes are in discovery and preclinical research. Any future clinical trial will be registered publicly and run under regulatory and ethics oversight.

Oncology, immunology, cardiometabolic disease, neurology and rare disease — areas with strong human biology and high unmet need.

Small molecules, antibodies, siRNA, mRNA and gene therapies. We choose the modality that fits the biology of each target.

AI ranks targets, generates and scores molecules and selects experiments. Qualified scientists review every recommendation and make every decision.

It is the share of AI-prioritised hypotheses confirmed in first-round wet-lab validation, as reported by the company. We publish the definition with the figure and will refine it as programmes mature.

Each collaboration runs in a segregated environment with encryption, access control and audit logging. Partner data is never used to train models for other parties without written consent.

Yes. We work with academic groups, biotech and pharmaceutical companies and investors. Visit the Partnering page or contact us.

We hire across machine learning, chemistry, biology and engineering. Send an open application through our contact form.

No. Please talk to your doctor about treatment options. We cannot provide medical advice or access to investigational medicines.